Here are six articles published by Becker's Hospital Review in the last week, featuring Cleveland Clinic's five-step strategy to address rising drug prices and the counterintuitive economic argument favoring price-gouging during a natural disaster, among other topics.
1. CMS to replace beneficiary-owned medical equipment damaged by Harvey
CMS on Thursday issued new guidance to help beneficiaries replace medical equipment and supplies that were lost or damaged from Hurricane Harvey.
2. FDA calls out EpiPen manufacturer for product flaws linked to patient deaths
Meridian Medical Technologies, a Pfizer subsidiary that manufacturers EpiPen's for Mylan, is in hot water for failing to adequately investigate complaints about the auto-injectors' efficacy.
3. Cleveland Clinic's 5-step strategy to address rising drug prices
Cleveland Clinic pharmacists and physicians developed a strategy to limit the financial impact of rising drug prices for two common heart medications, saving the hospital an estimated $8.5 million over the span of two years.
4. Economists' counterintuitive case for price-gouging during natural disasters: 4 things to know
More than 8,000 complaints have been made to the Florida attorney general's office over price spikes for items like food, gas and ice following Hurricane Irma. While most Americans scorn companies for raising prices after a natural disaster, some economists believe price gouging is actually beneficial.
5. Supply chain inefficiencies leave $23B in potential savings on the table for hospitals
U.S. hospitals could lower annual supply expenses by about $23 billion in total by improving supply chain processes and adjusting product use.
6. Physicians rarely disclose payments from pharma when promoting drugs on Twitter
Numerous cancer physicians who promote medications on Twitter and receive payments from drugmakers rarely acknowledge the conflict of interest.
More articles on supply chain:
Teva to sell contraceptive device business for $1.1B, divest remaining women's health assets
FDA reapproves leukemia drug 7 years after pulled from market
Supply chain inefficiencies leave $23B in potential savings on the table for hospitals